AMCI - Amnestic Mild Cognitive Impairment

3

Review clinical trials related to AMCI - Amnestic Mild Cognitive Impairment. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).

Participants needed: 100
Trial details
Phase: Phase 2Age: 55+Biological sex: AllType: InterventionalSponsor: Johns Hopkins UniversityUpdated: Jun 17, 2026Locations: 1
Eligibility criteria

Mild Cognitive Impairment (MCI) as defined by Albert et al.2 including subjectiv... [+8]

Less than 55 years of age to reduce likelihood of including individuals with fro... [+12]

Status: Recruiting

Neurocognitive Assessment Platform 4 Alzheimer

The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers. The Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data. The study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.

Participants needed: 100
Trial details
Age: 55-80Biological sex: AllType: ObservationalSponsor: IRCCS San RaffaeleUpdated: Jan 22, 2026Locations: 1Duration: 12 Months
Eligibility criteria

Signature of informed consent [+7]

Rejection of informed consent [+6]

Status: Recruiting

Effects of Photobiomodularion on Brain Connectivity and Cognitive Function in Cognitive Impairment

The goal of this clinical trial is to learn if transcranial photobiomodulation (t-PBM), a light-based brain therapy, can help improve memory and cognitive skills in older adults with amnestic mild cognitive impairment (aMCI). This condition involves memory problems that are greater than normal aging and may increase the chance of developing Alzheimer's disease. The main questions this study aims to answer are: 1. Does t-PBM, when used together with cognitive training, improve memory and cognitive skills? 2. Does t-PBM change how certain brain areas communicate with each other, especially in the default mode network (DMN)? Researchers will compare: t-PBM plus cognitive training to sham (inactive) t-PBM plus the same cognitive training to see if the active light treatment leads to better cognitive improvement and healthier brain activity. Participants will: * Provide a blood sample so the research team can create a genetic profile; * Complete cognitive tests before and after the 4-week program; * Meet with a dietitian before and after the program so the research team can make sure diet stays consistent and does not influence brain results; * Have a brain fMRI scan before and after treatment to measure brain connectivity changes; * Take part in eight sessions of cognitive training; * Receive either active t-PBM or sham t-PBM during these sessions.

Participants needed: 60
Trial details
Age: 55+Biological sex: AllType: InterventionalSponsor: Uskudar UniversityUpdated: Dec 17, 2025Locations: 2
Eligibility criteria

Age 55 years or older [+1]

Presence of a neurological disorder [+2]